Clinical Trials Logo

Filter by:
NCT ID: NCT03529526 Recruiting - Clinical trials for Advanced Solid Tumors

Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors

Start date: May 21, 2018
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, dose-escalation phase I study to assess the safety, tolerability and preliminary efficacy of KN046 in participants with all advanced solid tumors who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) or a biological effective dose (BED), to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of KN046 as a single agent in adult participants with advanced solid tumors

NCT ID: NCT03529513 Completed - Clinical trials for Major Depressive Episode

Medibio DDA Confirmatory Performance Study

Start date: August 18, 2017
Phase:
Study type: Observational

This study will determine whether the Medibio Depression Diagnostic Aid exceeds minimally acceptable thresholds for sensitivity and sensitivity in cases with a current depression episode and non-depressed controls.

NCT ID: NCT03528694 Not yet recruiting - Clinical trials for Non-muscle-invasive Bladder Cancer

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

POTOMAC
Start date: May 31, 2018
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer.

NCT ID: NCT03523819 Recruiting - Solid Tumor, Adult Clinical Trials

A Study of CS1002 in Subjects With Advanced Solid Tumors

Start date: April 26, 2018
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, multiple dose, dose escalation phase I study to evaluate the clinical safety, tolerability, PK, and preliminary anti-tumor efficacy of CS1002.

NCT ID: NCT03522012 Recruiting - Pharmacokinetics Clinical Trials

Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers

Start date: October 17, 2017
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, 3-arm, parallel-group single-dose study to compare the PK, PD, safety, tolerability, and immunogenicity of LusiNEX (Mycenax tocilizumab) versus RoActemra (EU tocilizumab) and Actemra (US tocilizumab) after a single IV infusion of 4 mg/kg in healthy volunteers (hereafter referred to as subjects). The therapeutic dose of tocilizumab starts with 4 mg/kg and ranges to 12 mg/kg, considering 4 mg/kg is the lowest dose, the same has been selected for the study.

NCT ID: NCT03520452 Recruiting - Clinical trials for Endothelial Dysfunction

Effect of Chlorogenic Acids on the Human Vasculature

Start date: March 14, 2018
Phase: N/A
Study type: Interventional

This study evaluates effects of different doses of chlorogenic acids on vascular health.

NCT ID: NCT03517722 Recruiting - Clinical trials for Lupus Erythematosus, Systemic

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Start date: April 16, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard of care treatments.

NCT ID: NCT03517449 Not yet recruiting - Clinical trials for Endometrial Neoplasms

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

Start date: May 16, 2018
Phase: Phase 3
Study type: Interventional

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to treatment of physician's choice.

NCT ID: NCT03517176 Not yet recruiting - Pancreatic Cancer Clinical Trials

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Start date: June 1, 2018
Phase: Phase 1
Study type: Interventional

CEND-1, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

NCT ID: NCT03516123 Not yet recruiting - Solid Tumor, Adult Clinical Trials

A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Start date: May 2018
Phase: Phase 1
Study type: Interventional

This is a multicenter, open label, dose escalation & expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006.